To address continuing concerns of misuse, abuse, addiction, and overdose of prescription stimulants, a class of drugs used to treat narcolepsy, the US Food and Drug Administration (FDA) is requiring updates to the Boxed Warning and other information to ensure the prescribing information is made consistent across the entire class of these medicines. The current…
Four individuals have been selected as the 2023 Sleep Research Society (SRS) award recipients for their contributions to the organization, sleep and circadian science, and public health. They will be recognized Monday, June 5, during the plenary session of the SLEEP 2023 annual meeting of the Associated Professional Sleep Societies in Indianapolis. “The SRS awards…
Five individuals have been selected as the 2023 American Academy of Sleep Medicine (AASM) award recipients for their contributions to the field of sleep medicine. They will be recognized Monday, June 5, during the plenary session of the SLEEP 2023 annual meeting of the Associated Professional Sleep Societies in Indianapolis. “I congratulate this year’s award…
Data from Apnimed’s MARIPOSA phase 2b trial—an efficacy, safety, and dose-finding study of one-month duration of its drug candidate for obstructive sleep apnea (OSA)—will be featured in an oral presentation and a poster presentation at The American Thoracic Society’s ATS 2023 International Conference in Washington, DC. “ATS 2023 will be our first opportunity to present…
Zevra Therapeutics Inc, formerly KemPharm, announced KP1077, its leading clinical candidate for treating idiopathic hypersomnia, is advancing with plans to expand into narcolepsy. Zevra reported continued advancement of a phase 2 clinical trial evaluating KP1077 as a treatment for idiopathic hypersomnia. Interim efficacy and safety data are expected as early as the third quarter, with…
By Chaunie Brusie, RN, BSN In March, the US Food and Drug Administration (FDA) cleared the next generation of Wesper’s patch-based home sleep testing system for assisting in the identification of sleep apnea in adult patients. Unlike the company’s first-generation device, the new design has longitudinal sleep monitoring at the forefront. The flexible abdominal and…
Philips announced that risk assessments have been completed for CPAP and BiPAP sleep therapy devices under the June 2021 recall, and the company has provided a summary to the US Food and Drug Administration and other authorities for review. This set of devices includes the first-generation DreamStation, System One, and DreamStation Go devices, representing approximately…
By Alice Vernon, Aberystwyth University You wake up in the middle of the night. The room is dark except for the faint glow of the moon through your window. But something’s wrong. A weight presses down on your limbs, digs deep into the flesh of your stomach, and squeezes the air from your lungs. You…
Eight years after planting New Life Fellowship Church in Queens, I was exhausted. The pressure of preaching and teaching weekly messages, along with the rest of my leadership responsibilities, left me depleted. Although our ministry was growing, I often felt like I was gaining the world but losing my own soul. This crisis launched me…
My wife, Julie, and I have been parents now for 43 years. During that time, God has graciously given us 6 children and 22 grandchildren, with more on the way (grandchildren, not children!). That’s a lot of parenting experience, even if many of our experiences only showed how confused we were at the time. When…